Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Mayer, S. Schulz, I. Bernlochner, T. Morath, S. Braun, J. Hausleiter, S. Massberg, H. Schunkert, K. Laugwitz, A. Kastrati, D. Sibbing (2014)
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivityThrombosis and Haemostasis, 112
L. Mauri, Wen-hua Hsieh, J. Massaro, K. Ho, R. D'Agostino, D. Cutlip (2007)
Stent thrombosis in randomized clinical trials of drug-eluting stents.The New England journal of medicine, 356 10
G. Campo, G. Parrinello, P. Ferraresi, B. Lunghi, M. Tebaldi, M. Miccoli, J. Marchesini, F. Bernardi, R. Ferrari, M. Valgimigli (2011)
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.Journal of the American College of Cardiology, 57 25
S. Rao, David Dai, S. Subherwal, W. Weintraub, R. Brindis, J. Messenger, R. Lopes, E. Peterson (2012)
Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients.JACC. Cardiovascular interventions, 5 9
T. Cuisset, G. Cayla, C. Frère, J. Quilici, R. Poyet, B. Gaborit, L. Bali, P. Morange, M. Alessi, J. Bonnet (2009)
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 5 3
D. Sibbing, S. Schulz, S. Braun, T. Morath, Julia Stegherr, J. Mehilli, A. Schömig, N. Beckerath, A. Kastrati (2010)
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placementJournal of Thrombosis and Haemostasis, 8
G. Parodi, R. Marcucci, R. Valenti, A. Gori, A. Migliorini, B. Giusti, P. Buonamici, G. Gensini, R. Abbate, D. Antoniucci (2011)
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.JAMA, 306 11
J. Siller-Matula, M. Francesconi, C. Dechant, B. Jilma, G. Maurer, G. Delle-Karth, G. Gouya, K. Ruzicka, A. Podczeck-Schweighofer, G. Christ (2013)
Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.International journal of cardiology, 167 5
G. Stone, B. Witzenbichler, G. Weisz, M. Rinaldi, F. Neumann, C. Metzger, T. Henry, D. Cox, Peter Duff, E. Mazzaferri, P. Gurbel, Ke Xu, H. Parise, A. Kirtane, B. Brodie, R. Mehran, T. Stuckey (2013)
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyThe Lancet, 382
F. Mangiacapra, G. Patti, E. Barbato, A. Peace, E. Ricottini, V. Vizzi, L. Gatto, A. D’Ambrosio, B. Bruyne, W. Wijns, G. Sciascio (2012)
A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.JACC. Cardiovascular interventions, 5 3
O. Mokhtar, G. Lemesle, S. Arméro, J. Mancini, Caroline Bonello, Iliassou Tahirou, P. Barragan, F. Dignat-George, L. Camoin-Jau, F. Paganelli, L. Bonello (2010)
Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention.Thrombosis research, 126 2
B. Doyle, C. Rihal, D. Gastineau, D. Holmes (2009)
Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice.Journal of the American College of Cardiology, 53 22
R. Mehran, S. Rao, Deepak Bhatt, C. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J. Sabik, D. Cutlip, M. Krucoff, E. Ohman, P. Steg, H. White (2011)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research ConsortiumCirculation, 123
W. Dewilde, T. Oirbans, F. Verheugt, J. Kelder, B. Smet, J. Herrman, T. Adriaenssens, M. Vrolix, A. Heestermans, M. Vis, Jan Tijsen, A. Hof, J. Berg (2013)
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 381
S. Steinhubl, A. Kastrati, P. Berger (2007)
Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs.American heart journal, 154 1
P. Steg, K. Huber, F. Andreotti, H. Arnesen, D. Atar, L. Badimón, J. Bassand, R. Caterina, J. Eikelboom, D. Gulba, M. Hamon, G. Helft, K. Fox, S. Kristensen, S. Rao, F. Verheugt, P. Widimsky, U. Zeymer, J. Collet (2011)
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.European heart journal, 32 15
Tina Slottow, L. Bonello, Rekha Gavini, Patricia Beauzile, Steven Sushinsky, M. Scheinowitz, Kimberly Kaneshige, Zhenyi Xue, R. Torguson, U. Tantry, A. Pichard, L. Satler, W. Suddath, K. Kent, P. Gurbel, R. Waksman (2009)
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.The American journal of cardiology, 104 4
J. Eikelboom, S. Mehta, Sonia Anand, C. Xie, K. Fox, S. Yusuf (2006)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 114
D. Hazarbasanov, V. Velchev, B. Finkov, A. Postadjian, E. Kostov, N. Rifai, D. Aradi (2012)
Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary interventionJournal of Thrombosis and Thrombolysis, 34
R. Paniccia, E. Antonucci, N. Maggini, E. Romano, A. Gori, R. Marcucci, D. Prisco, R. Abbate (2009)
Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy.American journal of clinical pathology, 131 6
S. Manzano-Fernández, F. Pastor, F. Marín, F. Cambronero, C. Caro, D. Pascual-Figal, I. Garrido, E. Pinar, M. Valdés, G. Lip (2008)
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.Chest, 134 3
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
G. Stone, James Ware, Michel Bertrand, A. Lincoff, Jeffrey Moses, E. Ohman, Harvey White, F. Feit, Antonio Colombo, B. McLaurin, David Cox, S. Manoukian, M. Fahy, Tim Clayton, R. Mehran, S. Pocock, for Investigators (2007)
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.JAMA, 298 21
M. Hamon, E. Filippi-Codaccioni, J. Riddell, O. Lepage (2007)
Prognostic impact of major bleeding in patients with acute coronary syndromes.A systematic review and meta-analysis.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 3 3
M. Price, P. Berger, P. Teirstein, J. Tanguay, D. Angiolillo, D. Spriggs, S. Puri, M. Robbins, K. Garratt, O. Bertrand, M. Stillabower, Joseph Aragon, D. Kandzari, Curtiss Stinis, Michael Lee, S. Manoukian, C. Cannon, N. Schork, E. Topol (2011)
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.JAMA, 305 11
P. Gurbel, K. Bliden, W. Samara, Jason Yoho, K. Hayes, M. Fissha, U. Tantry (2005)
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.Journal of the American College of Cardiology, 46 10
J. Collet, T. Cuisset, G. Rangé, G. Cayla, S. Elhadad, C. Pouillot, P. Henry, P. Motreff, D. Carrié, Z. Boueri, L. Belle, E. Belle, H. Rousseau, P. Aubry, J. Monségu, P. Sabouret, S. O’Connor, J. Abtan, M. Kerneis, C. Saint-Etienne, O. Barthelemy, F. Beygui, J. Silvain, E. Vicaut, G. Montalescot (2012)
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.The New England journal of medicine, 367 22
F. Verheugt, S. Steinhubl, M. Hamon, H. Darius, P. Steg, M. Valgimigli, S. Marso, S. Rao, A. Gershlick, A. Lincoff, R. Mehran, G. Stone (2011)
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.JACC. Cardiovascular interventions, 4 2
Y. Naruse, A. Sato, T. Hoshi, N. Takeyasu, Y. Kakefuda, Mayu Ishibashi, M. Misaki, D. Abe, K. Aonuma (2013)
Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic RangeCirculation: Cardiovascular Interventions, 6
T. Cuisset, C. Grosdidier, A. Loundou, J. Quilici, M. Loosveld, L. Camoin, M. Pankert, S. Beguin, M. Lambert, P. Morange, J. Bonnet, M. Alessi (2013)
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).JACC. Cardiovascular interventions, 6 8
P. Vranckx, S. Leonardi, M. Tebaldi, S. Biscaglia, G. Parrinello, S. Rao, R. Mehran, M. Valgimigli (2014)
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.European heart journal, 35 37
G. Stone, B. Witzenbichler, G. Guagliumi, J. Peruga, B. Brodie, Dariusz Dudek, Ran Kornowski, Franz Hartmann, B. Gersh, S. Pocock, G. Dangas, S. Wong, Ajay Kirtane, H. Parise, R. Mehran (2008)
Bivalirudin during primary PCI in acute myocardial infarction.The New England journal of medicine, 358 21
A. Michelson, A. Frelinger, M. Furman (2006)
Current options in platelet function testing.The American journal of cardiology, 98 10A
A. Lincoff, J. Bittl, R. Harrington, F. Feit, N. Kleiman, J. Jackman, I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr, E. Cohen, A. Betriu, W. Desmet, D. Kereiakes, W. Rutsch, R. Wilcox, P. Feyter, A. Vahanian, E. Topol (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.JAMA, 289 7
I. Mrdovic, L. Savic, G. Krljanac, M. Ašanin, J. Perunicić, N. Antonijević, R. Lasica, J. Marinković, N. Kocev, Z. Vasiljevic (2013)
Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial.International journal of cardiology, 167 4
D. Aradi, A. Kirtane, L. Bonello, P. Gurbel, U. Tantry, K. Huber, M. Freynhofer, J. Berg, P. Janssen, D. Angiolillo, J. Siller-Matula, R. Marcucci, G. Patti, F. Mangiacapra, M. Valgimigli, O. Morel, T. Palmerini, M. Price, T. Cuisset, A. Kastrati, G. Stone, D. Sibbing (2015)
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.European heart journal, 36 27
V. Serebruany, S. Rao, Matthew Silva, J. Donovan, Abir Kannan, L. Makarov, S. Goto, D. Atar (2010)
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.European heart journal, 31 2
G. Campo, F. Saia, P. Guastaroba, J. Marchesini, E. Varani, A. Manari, F. Ottani, S. Tondi, R. Palma, A. Marzocchi (2011)
Prognostic impact of hospital readmissions after primary percutaneous coronary intervention.Archives of internal medicine, 171 21
D. Sibbing, S. Steinhubl, S. Schulz, A. Schömig, A. Kastrati (2010)
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.Journal of the American College of Cardiology, 56 4
Jason Lindsey, S. Marso, M. Pencina, J. Stolker, K. Kennedy, C. Rihal, G. Barsness, R. Piana, S. Goldberg, D. Cutlip, N. Kleiman, D. Cohen (2009)
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry.JACC. Cardiovascular interventions, 2 11
K. Mayer, I. Bernlochner, S. Braun, S. Schulz, M. Orban, T. Morath, Lisena Cala, P. Hoppmann, H. Schunkert, K. Laugwitz, A. Kastrati, D. Sibbing (2014)
Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry.Journal of the American College of Cardiology, 64 9
N. Breet, J. Werkum, H. Bouman, J. Kelder, H. Ruven, E. Bal, V. Deneer, A. Harmsze, J. Heyden, B. Rensing, M. Suttorp, C. Hackeng, J. Berg (2010)
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.JAMA, 303 8
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
P. Gum, K. Kottke-Marchant, P. Welsh, Jennifer White, E. Topol (2003)
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.Journal of the American College of Cardiology, 41 6
G. Montalescot, U. Sechtem, S. Achenbach, F. Andreotti, C. Arden, A. Budaj, R. Bugiardini, F. Crea, T. Cuisset, C. Mario, J. Ferreira, B. Gersh, A. Gitt, J. Hulot, N. Marx, L. Opie, M. Pfisterer, E. Prescott, F. Ruschitzka, M. Sabaté, R. Senior, D. Taggart, E. Wall, C. Vrints, J. Zamorano, H. Baumgartner, Jeroen Bax, H. Bueno, V. Dean, C. Deaton, Ç. Erol, R. Fagard, R. Ferrari, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M. Piepoli, P. Ponikowski, P. Sirnes, J. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, M. Valgimigli, M. Claeys, N. Donner‐Banzhoff, Herbert Frank, C. Funck-Brentano, O. Gaemperli, J. González-Juanatey, M. Hamilos, S. Husted, S. James, K. Kervinen, S. Kristensen, A. Maggioni, A. Pries, F. Romeo, L. Rydén, M. Simoons, P. Steg, A. Timmis, A. Yıldırır (2013)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.European heart journal, 34 38
T. Palmerini, P. Généreux, A. Caixeta, Ecaterina Cristea, A. Lansky, R. Mehran, D. Riva, M. Fahy, Ke Xu, G. Stone (2012)
A new score for risk stratification of patients with acute coronary syndromes undergoing percutaneous coronary intervention: the ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy-Percutaneous Coronary Intervention) risk score.JACC. Cardiovascular interventions, 5 11
B. Bruyne, N. Pijls, B. Kalesan, E. Barbato, P. Tonino, Z. Piróth, N. Jagic, S. Möbius‐Winkler, G. Rioufol, N. Witt, P. Kala, P. MacCarthy, Thomas Engström, K. Oldroyd, K. Mavromatis, G. Manoharan, P. Verlee, O. Frøbert, N. Curzen, Jane Johnson, P. Jüni, W. Fearon (2012)
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.The New England journal of medicine, 367 11
D. Angiolillo, A. Fernández-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. Bass, M. Costa (2007)
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.Journal of the American College of Cardiology, 49 14
P. Legalery, F. Schiele, M. Séronde, N. Meneveau, H. Wei, Katy Didier, M. Blonde, Fiona Caulfield, J. Bassand (2005)
One-year outcome of patients submitted to routine fractional flow reserve assessment to determine the need for angioplasty.European heart journal, 26 24
M. Würtz, E. Grove, Lise Wulff, A. Kaltoft, H. Tilsted, L. Jensen, A. Hvas, S. Kristensen (2010)
Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.JACC. Cardiovascular interventions, 3 8
N. Breet, J. Werkum, H. Bouman, J. Kelder, A. Harmsze, C. Hackeng, J. Berg (2011)
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary interventionHeart, 97
G. Patti, V. Pasceri, V. Vizzi, E. Ricottini, G. Sciascio (2011)
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).The American journal of cardiology, 107 7
P. Roy, L. Bonello, R. Torguson, A. Labriolle, G. Lemesle, T. Slottow, D. Steinberg, Kimberly Kaneshige, Zhenyi Xue, L. Satler, K. Kent, W. Suddath, A. Pichard, J. Lindsay, R. Waksman (2008)
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.The American journal of cardiology, 102 12
Background Bleeding after percutaneous coronary interventions (PCI) is an important complication with impact on prognosis. Aim To evaluate the predictive value of enhanced platelet responsiveness to dual antiplatelet therapy with aspirin and clopidogrel, for bleeding, after elective PCI. Methods and Results We performed multiple electrode aggregometry (MAE) platelet functional tests induced by arachidonic acid (ASPI) and adenosine‐diphosphate (ADP) before PCI, and 24 hours after PCI, in 481 elective PCI patients who were followed‐up for an average of 15.34 ± 7.19 months. Primary end point was the occurrence of any bleeding, while ischemic major adverse cardiovascular event (MACE) was a secondary endpoint. The incidence of total, BARC ≤ 2, and BARC ≥ 3 bleeding, according to BARC classification, was 19, 18, and 1%, respectively. Groups with any, and BARC ≤ 2 bleeding, had a lower average value of MAE ADP test after 24 hours, compared to the group without bleeding: 45.30 ± 18.63 U versus 50.99 ± 19.01 U; P = 0.005; and 45.75 ± 18.96 U versus 50.99 ± 18.99 U; P = 0.01; respectively. Female gender (HR 2.11; CI 1.37–3.25; P = 0.001), previous myocardial infarction (HR 0.56; CI 0.37–0.85; P = 0.006), lower body mass (HR 0.78; CI 0.62–0.98; P = 0.03), and MAE ADP test after 24 hours (HR 0.75; CI 0.61–0.93; P = 0.009) were the independent predictors for any bleeding by Cox univariate analysis. After adjustment, MAE ADP test after 24 hours, was the only independent predictor for any (HR 0.7; CI 0.56–0.87; P = 0.002), and BARC ≤ 2 (HR 0.71; CI 0.56–0.89; P = 0.003) bleeding, by Cox multivariate analysis. Conclusion MAE ADP test before and after PCI, was associated with any, and BARC ≤ 2 bleeding after elective PCI.
Journal of Interventional Cardiology – Wiley
Published: Dec 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.